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Side effectsIn the early 1990s, within three years of cloning of endothelin receptors, orally active endothelin receptor an-
tagonists (ERAs) were tested in humans and the ﬁrst clinical trial of ERA therapy in humans was published in
1995. ERAs were subsequently tested in clinical trials involving heart failure, pulmonary arterial hyperten-
sion, resistant arterial hypertension, stroke/subarachnoid hemorrhage and various forms of cancer. The re-
sults of most of these trials – except those for pulmonary arterial hypertension and scleroderma-related
digital ulcers – were either negative or neutral. Problems with study design, patient selection, drug toxicity,
and drug dosing have been used to explain or excuse failures. Currently, a number of pharmaceutical compa-
nies who had developed ERAs as drug candidates have discontinued clinical trials or further drug develop-
ment. Given the problems with using ERAs in clinical medicine, at the Twelfth International Conference on
Endothelin in Cambridge, UK, a panel discussion was held by clinicians actively involved in clinical develop-
ment of ERA therapy in renal disease, systemic and pulmonary arterial hypertension, heart failure, and can-
cer. This article provides summaries from the panel discussion as well as personal perspectives of the
panelists on how to proceed with further clinical testing of ERAs and guidance for researchers and decision
makers in clinical drug development on where future research efforts might best be focused.
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Twenty years ago – only a few years after cloning of the twomamma-
lian endothelin (ET) receptors (Arai et al., 1990; Sakurai et al., 1990) –
orally active ET receptor antagonists (ERAs) were discovered (Atkinson
and Pelton, 1992; Bazil et al., 1992; Breu et al., 1993; Clozel et al., 1993,
1994; Fukuroda et al., 1992; Ihara et al., 1991, 1992; Spinella et al.,
1991), opening new therapeutic opportunities for treating human dis-
ease (Battistini et al., 2006). Many pharmaceutical companies identiﬁed
and synthesized orally active ETA receptor-selective or non-selective,
ETA/ETB ERAs as drug candidates, which rapidly were put into clinical
testing (Barton and Kohan, 2011; Battistini et al., 2006). In 1995, only
5 years after cloning of ET receptors (Arai et al., 1990; Sakurai et al.,
1990), the ﬁrst clinical study using ERA therapy in patients with severe
heart failure was published (Kiowski et al., 1995). At the time when
this and other studies were conducted, the biology of ET and its receptors
in health and disease was only beginning to be understood (Barton and
Yanagisawa, 2008). Subsequently, a large number of Phase II and III trials
were conducted for a variety of disorders, including heart failure, cancer,
pulmonary arterial hypertension, arterial hypertension, proteinuric renal
disease, and autoimmune diseases (Battistini et al., 2006). Despite such
intensive efforts, ERAs have been approved by theU.S. Food andDrugAd-
ministration for only two drugs and only two indications: bosentan and
ambrisentan in pulmonary arterial hypertension (Rubin et al., 2002;
Galie et al., 2008a,b), and bosentan in scleroderma-related digital ulcers
(Dhillon, 2009) (Fig. 1). Currently, clinical testing is ongoing forEndothelin
Receptor
Antagonism
Pulmonary Arterial Hypertension
Proteinuric Renal Disease Scleroderma Digital Ulcers
Cancer
Arterial Hypertension Autoimmune Diseases
Heart Failure
Fig. 1. Human diseases for which ERA therapy has been evaluated in clinical trials.
Black print indicates disease indication for which the use of ERAs as therapeutics has
been approved by the U.S. Food and Drug Administration, gray print indicates disease
indications for which clinical trials have been completed or are currently ongoing but
have not yet received approval for clinical use by the FDA or other regulatory agencies.
See text for details.subarachnoid hemorrhage, proteinuric renal disease, and coronary artery
disease (Barton and Yanagisawa, 2008).
We have recently discussed some of the causes that led to failure of
clinical trials using ERAs (including study design, patient selection, and
drug dosing) (Barton and Kohan, 2011), and have re-emphasized the
need for access to all data obtained in previous clinical ERA trials as initial-
ly proposed by Kelland and Webb (2007). In view of the therapeutic
opportunities, combined with the difﬁculties that the ﬁeld has experi-
enced, a panel discussion by clinicians actively involved in clinical testing
of ERAs was held at the Twelfth International Conference on Endothelin.
This article represents a summary of the panel discussion; the following
four sections were written by the relevant panelist on renal disease,
heart failure, pulmonary arterial hypertension, or cancer. Each section de-
scribes data and personal views on the current state of ERA drug therapy
in human disease; of particular importance, guidance is provided on how
to best move forward to realize the potential of this class of drugs.
Endothelin receptor antagonism in patients with chronic kidney
disease and arterial hypertension
Endothelins are important regulators of kidney function and arterial
pressure (Dhaun et al., 2006; Kohan et al., 2011a,b,c). Endogenous ET
controls renal cell growth and proliferation, ﬂuid and electrolyte excre-
tion, renal vascular tone, immune function and other parameters
(Dhaun et al., 2006; Kohan et al., 2011a,b,c; Schneider et al., 2007).
Renal ET-1 production is increased in numerous forms of renal disease
(Barton, 2010; Kohan, 2010); as will be described, the ET system plays
an important role in renal diseases and blockade of this system has
substantial potential beneﬁt in helping to prevent kidney disease
progression.
Chronic kidney disease and arterial hypertension are good targets for
endothelin receptor antagonists
ET has been strongly implicated in the pathogenesis and progression
of experimental chronic kidney disease (CKD), including diabetic
nephropathy, glomerulonephritis, hypertensive nephrosclerosis, re-
duced renal mass and others (Barton, 2010; Benigni et al., 1998, 2004;
Dhaun et al., 2006; Kohan, 2010; Orisio et al., 1993). ERAs, and particu-
larly ETA receptor blockers, confer substantial nephroprotective effects
in various models of CKD (Barton, 2008; Benigni et al., 1998, 2004;
Dhaun et al., 2006; Kohan, 2010; Neuhofer and Pittrow, 2009). In an
exciting study, combined ERA and angiotensin receptor blocker treat-
ment induced regression of renal injury in experimental diabetes
(Gagliardini et al., 2009). Clinical trials (Phase II or III) with various
ERAs (including atrasentan, avosentan, darusentan, and sitaxsentan)
showed reduced proteinuria in patients with CKD (Dhaun et al., 2011;
Honing et al., 2000; Kohan et al., 2011a,b,c; Mann et al., 2010; Weber
et al., 2009; Wenzel et al., 2009). ET also has been strongly linked
with hypertension (Bakris et al., 2010; Battistini et al., 2006; Kohan et
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2002). ERAs, whether targeting ETA or both ETA and ETB receptors, sig-
niﬁcantly reduced arterial pressure in patients with essential hyperten-
sion, treatment-resistant hypertension and/or CKD (Bakris et al., 2010;
Goddard et al., 2004; Lazich and Bakris, 2011; Nakov et al., 2002).
Despite these successes with ERAs in CKD and hypertension, no
ERAs have been approved by any regulatory agency and clinical trials
have markedly decreased. Currently, only atrasentan is being actively
studied for use in patients with CKD (Andress et al., 2012; Kohan et
al., 2011a,b,c) while there are no on-going clinical trials with ERAs
in arterial hypertension.
The reasons for this death of ERA trials in CKD, as well as the cur-
rent lack of trials with ERAs in hypertension, are varied, and as will be
discussed, illustrate how problems with study design, selection of pri-
mary endpoints, and adverse effects have greatly limited the clinical
application of ERAs in diseases that have shown every indication
that they will be highly responsive to ET receptor antagonism.
Adverse effects of eras in human trials in CKD: could they have been
avoided?
ERAs are associated with adverse effects, including ﬂuid retention,
hepatotoxicity, testicular toxicity and teratogenesis. Like inhibitors of
the angiotensin system such as ACEI and ARBs, ERAs are absolutely
contraindicated in pregnancy. ERA-induced testicular toxicity in ex-
perimental animals is described in drug company product literature
(for both ETA receptor selective and non-selective antagonists) or in
dissertations without presenting the actual data (Grass, 2006). In
the product literature for bosentan, a non-selective sulphonamide
ERA, it is stated that many ERAs induce marked atrophy of the semi-
niferous tubules of the testes, reduce sperm counts, and decrease
male fertility in rats when administered for longer than 10 weeks. It
is also stated that these effects of bosentan in humans appear to be ir-
reversible. Despite such ﬁndings, amazingly no peer-reviewed study
involving either experimental animals or patients devoted to
ERA-induced testicular toxicity has been published. An unpublished
open-label study in patients with pulmonary hypertension deter-
mined that bosentan can reduce sperm count in men. Given the po-
tential seriousness of this side effect, one cannot help but wonder
why the scientiﬁc community has not investigated this in more detail,
and particularly under the scrutiny of peer review. Whether ERA
treatment may differently affect testicular toxicity in humans under
disease conditions such as diabetes (which so far has been studied
only in experimental animals (Cai et al., 2000)) is currently unknown.
Hepatotoxicity is a concern with ERAs, and particularly those that
contain a sulfonamide moiety (Hoeper, 2009; Hoeper et al., 2009;
McGoon et al., 2009). Sitaxentan, a sulfonamide-based ERA, was being
studied in CKD and had demonstrated an antiproteinuric effect (Dhaun
et al., 2011). However, in 2010, four cases of fatal liver failure, possibly
idiosyncratic, were reported in approximately 2000 sitaxsentan-treated
patients. This contrasts with no cases of liver failure in over 90,000
patients on either bosentan or ambrisentan (Galie et al., 2011). Conse-
quently, sitaxsentan was withdrawn from the market.
Perhaps the most glaring example of how an ERA adverse effect has
affected clinical trials in CKD relates to ERA-induced ﬂuid retention. All
ERAs used in clinical trials, regardless of receptor isoform speciﬁcity,
cause ﬂuid retention (Battistini et al., 2006), including bosentan,
darusentan, tezosentan, ambrisentan, sitaxsentan, avosentan, zibotentan
and atrasentan. The degree of ﬂuid retention is dose-dependent and is
related to the individual's propensity, being exacerbated by congestive
heart failure and renal insufﬁciency. The importance of ﬂuid retention is
best illustrated by a recently failed trial using avosentan (ASCEND trial)
in patients with diabetic nephropathy with glomerular ﬁltration rates
between 15 and 60 ml/min (i.e., moderate to advanced CKD (Mann et
al., 2010)). This Phase III trial was conductedwithout any preceding pub-
lications on avosentan-induced ﬂuid retention in health or in kidneydisease. While avosentan signiﬁcantly reduced proteinuria, it caused
marked ﬂuid retention (about 50% of patients in the avosentan groups
had ﬂuid retention from mild to severe, as compared to about 33% in
the placebo group). Consequently, the trial was prematurely terminated.
In retrospect, the doses employed in this trial were too high since a Phase
II study, published a year before the results of the ASCEND trial were pub-
lished, showed that avosentan exerted antiproteinuric effects at substan-
tially lower doses than those used in the ASCEND trial and caused only
modest ﬂuid retention (Wenzel et al., 2009). Clearly, the question must
be raised as to the choice of doses employed in the ASCEND trial, and
how this might have been better informed if studies, particularly
peer-reviewed, were conducted in advance of undertaking a large
Phase III trial.
Problems with study design have impacted clinical trials of eras in arterial
hypertension
The substantial preclinical literature and some clinical studies
suggested that ERAs could be effective antihypertensive agents, particu-
larly in the setting of resistant hypertension (Barton et al., 2006; Barton
andYanagisawa, 2008). In a Phase III trial in resistant hypertension (DO-
RADO), darusentan, a relatively ETA receptor-selective antagonist, re-
duced proteinuria and lowered blood pressure in patients with CKD
(Weber et al., 2009). In a second Phase III trial (DORADO-AC),
darusentan reduced ambulatory blood pressure to a greater degree
than the active control, guanfacine (Bakris et al., 2010). However, the
primary endpoint of ofﬁce blood pressure reduction was not met,
hence the company decided to discontinue further development of
darusentan for the clinical indication of resistant hypertension. Thus,
due to the unfortunate choice of the primary endpoint, as well as other
issues such as side effects (particularly dose-related ﬂuid-retention)
and economical issues caused by costs required to perform additional
Phase I and II trials in arterial hypertension (Barton and Kohan, 2011;
Lazich and Bakris, 2011; Webb, 2010), development of ERAs for the
treatment of arterial hypertension has been essentially abandoned.
Using lessons from the past to inform future era trials in kidney disease
and arterial hypertension
Moving forward, it is obvious that, as has been pointed out previous-
ly (Kelland and Webb, 2007), there must be increased efforts to fully
disclose and publish peer-reviewed studies, both experimental and
clinical, about ERA actions, pharmacology and adverse effects. It is real-
ized that the clock on ERAs is ticking; many of these drugs are nearing
the end of their patent life and companies must be highly selective
about clinical conditions for which they seek indications. Nonetheless,
CKD in particular, and possibly resistant hypertension, remain highly
attractive ERA targets.
How do we optimize future trials studying ERAs in kidney disease
and hypertension? First, patients must be carefully selected, excluding
the elderly (perhaps >80 years old) and patients with congestive
heart failure or advanced CKD (i.e. stage 4 or greater). The issue of
testicular safety in young men remains to be fully elucidated, so treat-
ment of these individuals must be approached cautiously. Second, the
dose of ERA must be carefully chosen and adjusted; a recent Phase IIA
trial with atrasentan in diabetic nephropathy demonstrated that careful
ERA dosing can largely avoid signiﬁcant ﬂuid retention, yet still have a
substantial antiproteinuric effect (Kohan et al., 2011a,b,c). In addition,
the judicious use of diuretics, particularly early in the course of ERA
treatment, may substantially mitigate ﬂuid retention. Third, great care
must be paid to study design, including identiﬁcation of the optimal
endpoints and disease markers. Finally, while not extensively discussed
in this review, the bulk of literature supports the notion that selective
ETA receptor antagonists are likely to have a greater beneﬁcial effect
on kidney disease and blood pressure as compared to non-selective
ERAs. With careful attention to these aforementioned issues, there is
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cacious in the treatment of kidney disease and possibly hypertension,
giving us the ﬁrst new agents for treatment of these disorders in
many years.Endothelin receptor antagonism in patients with heart failure
Heart failure is common and may afﬂict people at any age but
most patients in most countries are aged >60 years (Cleland et al.,
2011, 2003). Up to one in three people will develop heart failure at
some time in their life (Bleumink et al., 2004; Lloyd-Jones et al.,
2002) but this might be a serious under-estimate due to inadequate
case ascertainment and frequent failure to identify or highlight
heart failure as a complication of other cardiac problems (Cleland et
al., 2007, 2009a,b). Most people who die of cardiac disease will ﬁrst
develop heart failure (Torabi et al., 2008, 2009).Prevalence and mortality of heart failure
The life-time risk of developing heart failure may be high, but the
prevalence at any moment is modest and probably at most 3% of
adults or about 2% of the entire population will have heart failure
(Cleland et al., 2001). This may be >100 million people worldwide
at any one time although differences in age and pathophysiology
are likely to be heterogeneous amongst regions. The disparity be-
tween incidence and prevalence reﬂects the high mortality (Torabi
et al., 2008). Once patients develop heart failure, annual mortality is
high, ranging from about 5% per year in stable, well-treated patients
with mild disease to more than 30% in patients who have
new-onset heart failure or who have experienced a recent hospitali-
zation for worsening symptoms (Cleland et al., 2011, 2009a,b;
Harjola et al., 2011). Heart failure is often a terminal process with
prognosis measured in days, weeks or months rather than years.
However, expert care can restore many patients to a good quality of
life for prolonged periods.Etiology and current therapies of heart failure
Effective management of hypertension and coronary artery and
valve disease will delay the onset of heart failure and reduce its inci-
dence in younger people. However, as life expectancy increases and
the proportion of the population aged >70 years rises, the prevalence
of heart failure will increase (Cleland et al., 2001). Patients who pre-
viously would have died of stroke or myocardial infarction will now
live longer after the onset of cardiovascular disease, which will fuel
a further increase in the prevalence and reported incidence of heart
failure, even if age-adjusted rates fall. Moreover, contemporary phar-
macological therapy may have tripled life expectancy and therefore,
provided the patient can be stabilized on therapy, this will also in-
crease the prevalence of heart failure (Cleland and Clark, 2003).
Heart failure is a complex,multi-dimensional clinical problemwith di-
verse pathophysiology both in terms of etiology and consequences. It is a
systemic disease caused by cardiac dysfunction. Ischemic heart disease,
hypertension and idiopathic dilated cardiomyopathy are key etiologies,
while pulmonary hypertension (Damy et al., 2010), atrial ﬁbrillation
(Shelton et al., 2010), renal dysfunction (de Silva et al., 2006a,b), and ane-
mia (de Silva et al., 2006a,b) may be causes and/or consequences of heart
failure. Some treatments, such as diuretics, may be applied generically to
all forms of heart failure, but most are directed at speciﬁc subgroups such
as valve disease, electrical disturbances or left ventricular systolic dys-
function. Good patient management requires in-depth knowledge of the
disease and its treatment as well as a more holistic assessment of the pa-
tients' needs.Endothelin in heart failure
Endothelin has many cardiovascular effects that may drive the pro-
gression of cardiovascular disease and heart failure. It is a powerful con-
strictor of both systemic and pulmonary arterioles and veins (Serneri et
al., 1995). These effects may be mitigated by increased prostaglandin
synthesis that develops with heart failure. Prostaglandin synthesis is
enhanced by ACE inhibitors and blocked by the administration of aspi-
rin (Cleland, 2006) and may increase the vasoconstrictor effects of ET
(Haynes and Webb, 1993). Endothelin may also cause myocyte hyper-
trophy, both vascular and myocardial, and ﬁbrosis. Its effects on renal
sodium handling are less certain (Modesti et al., 1998). Renal cortical
vasoconstriction may cause sodium retention but effects on the proxi-
mal renal tubule and other nephron segments, possibly mediated by
the ETA receptor, may causes natriuresis (Burnier and Forni, 2012;
Smolander et al., 2009, Kohan et al., 2011a,b,c). Endothelin also has pos-
itive inotropic and chronotropic effects on themyocardium (Barton and
Yanagisawa, 2008; Concas et al., 1989; Moravec et al., 1989; Watanabe
et al., 1989). Thus, as with most biological systems, the effects of inter-
ference are difﬁcult to predict.
Plasma concentrations of ET are increased in heart failure regard-
less of phenotype or disease etiology but in proportion to the severity
of symptoms (Rodeheffer et al., 1992). It is likely that much of the ac-
tions of endothelins are mediated by local concentrations (paracrine)
but infusing endothelin-1 to achieve the plasma concentrations ob-
served in disease causes vasoconstriction (Cowburn et al., 1998, 1999),
indicating that ET can also be considered an endocrine system. Infusing
endothelin-3, which is more selective for the ETB receptor, has similar
hemodynamic effects to endothelin-1 (Cowburn et al., 1999). In patients
with heart failure, the ETA receptor appears mainly responsible for the
hemodynamic consequences of ET excess while the ETB receptor ap-
pears mainly involved in ET clearance (Cowburn et al., 2005). Blockade
of ETB receptors has adverse hemodynamic consequence (Cowburn et
al., 2005). The paradoxical effects of ETB stimulation and blockade indi-
cate the complexity of the system, likely different populations of ETB re-
ceptors and the consequences of blocking ET clearance.
Plasma concentrations of ET or its precursors are strongly related
to prognosis in heart failure (Hulsmann et al., 1998; Omland et al.,
1994; Pacher et al., 1996; Rodeheffer et al., 1992). There is increasing
interest in the role of pulmonary hypertension and right heart dys-
function in patients with heart failure, which seem to be better guides
to prognosis than left ventricular dysfunction (Damy et al., 2010).
Plasma ET is more closely related to pulmonary vascular resistance
than other hemodynamic features of heart failure and this relation-
ship may be causal (Cody et al., 1992; Givertz et al., 2000; Good et
al., 1994; Ooi et al., 2002). Thus, ET could be an important driver of
this pathway of progression of heart failure. Experimental prevention
studies of myocardial infarction in mice and rats suggest that ERA
therapy initiated prior to or immediately after infarction can also pre-
vent myocardial remodeling (Mulder et al., 2000, 1998, 1997; Sakai et
al., 1996) but only one experimental study investigated ERA therapy
in animals with established heart failure and found no beneﬁt on sur-
vival (Vetter et al., 2006). A meta-analysis of prevention studies initi-
ating ERA immediately after experimental myocardial infarction also
found no beneﬁt on survival (Lee et al., 2003).
Clinical studies of ERAs in heart failure
Administration of bosentan, a non-selective ERA, to patients with
severe heart failure resulted in hemodynamic beneﬁts, with striking
reductions in systemic and pulmonary vascular resistances and atrial
pressures and a rise in cardiac output (Kiowski et al., 1995; Schalcher
et al., 2001; Sutsch and Barton, 1999; Sutsch et al., 1998). However,
blockade was associated with a reﬂex increase in circulating ET and
further activation of the renin–angiotensin system. The encouraging
hemodynamic results led to the ﬁrst of a series of randomized
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excuses were made for the neutral or negative results, including dose,
receptor selectivity or patient population but, so far, no change in strat-
egy has resulted in a convincingly positive result andmany studies even
showed trends to harm. In studies of chronic heart failure the main
problem appears to be ﬂuid retention, as evidence by weight gain,
more peripheral and pulmonary edema, and plasma volume expansion,
as evidenced by a fall in hemoglobin (Coletta et al., 2002; Packer et al.,
2005). There is no evidence of a beneﬁcial effect on cardiac remodeling
despite improved hemodynamics (Anand et al., 2004; Prasad et al.,
2006). In studies of acute heart failure, hypotension, renal dysfunction
and reductions in arterial oxygen tension, the latter suggesting worsen-
ing pulmonary ventilation/perfusion matching, appear to be important
problems (Coletta et al., 2002; Kaluski et al., 2003; McMurray et al.,
2007).
Heart failure has also been reported as a side effect of ERAs used for
other indications. Over amedian follow-upof 4 months, avosentan (ETA
selective) reduced blood pressure and micro-albuminuria in patients
with type-2 diabetesmellitus but causedweight gain and a fall in hemo-
globin, suggesting ﬂuid retention and plasma volume expansion (Mann
et al., 2010). This was accompanied by strong trends for worsening
renal function and an increased risk of developing heart failure (2.2%
on placebo versus >6.0% with avosentan; p=0.05) (Mann et al.,
2010). Mortality was 2.6% on placebo compared to >6.0% with
avosentan (ns). In a large study of prostate cancer, atrasentan (ETA se-able 1
linical trials investigating the effects of ERA therapy on symptoms, ventricular remodeling, or clinical outcome in patients with heart failure. Trial references: a, (Packer et al.,
005); b, (Coletta et al., 2002); c, (Louis et al., 2001); d, (Luscher et al., 2002); e, (Anand et al., 2004); f, (Prasad et al., 2006); g, (Coletta and Cleland, 2001); h, (Louis et al.,
001); i, (O'Connor et al., 2003); j, (Kaluski et al., 2003); k, (Cotter et al., 2004); l, (McMurray et al., 2007); ERA = endothelin receptor antagonist. # = death or hospitalization
r worsening heart failure during or within 48 h of completion of infusion. ACS = acute coronary syndrome. & = readmission but not otherwise speciﬁed. NA = not available.
Trial Agent Receptor N Duration
of follow-up
Death Worsening
HF
Comments
on ERA
Chronic heart failure Placebo ERA Placebo ERA
REACH-1a Bosentan
500 mg bid
ETA/B 369 ~6 m 8/125
(6.4%)
17/244
(7.0%)
27/125
(21.6%)
47/244
(19.3%)
Early excess of worsening
heart failure events
ENABLEb Bosentan
125 mg bd
ETA/B 1611 18 m 173/808
(21.4%)
160/805
(19.9%)
321/808 #
(39.7%)#
312/805#
(38.8%)
Fluid retention
ENCORc Enrasentan
Dose-ranging
ETA/B 419 9 m NA
(3.5%)
NA
(5.9%)
Adverse trend with enrasentan More adverse events
HEATd Darusentan
Dose-ranging
ETA 157 1 m 0/33
(0.0%)
4/124
(3.2%)
4/33
(12.1%)
29/124
(23.4%)
Headaches
EARTHe Darusentan
Dose-ranging
ETA 642 6 m 4/110
(3.6%)
26/532
(4.9%)
9/110
(8.2%)
53/532
(10.0%)
No beneﬁt on LV
remodeling
Chronic heart failure Enalapril Enrasentan Enalapril Enrasentan
Pennellf Enrasentan ETA/B 72 6 m 1/36
(2.8%)
1/36
(2.8%)
10/36
(27.8%)
8/36
(22.2%)
More favorable LV
remodeling with
enalapril (p=0.001)
Target Duration and
dose
N Duration of
follow-up
Death Worsening
HF
Comments on
tezosentan
Target Duration and dose
Acute heart failure all conducted with intravenous tezosentan (ETA/B)
RITZ-1g Symptoms 24–72 h
50 mg/h
669 1 m 17/339
(5.0%)
24/336
(7.1%)
39#
(11.5%)
51#
(15.4%)
Symptoms not
improved
RITZ-2h Hemodynamics 24 h
50–100 mg/h
285 1 m 5/94
(5.3%)
16/191
(8.4%)
22/94
(23.4%)
26/191
(13.6%)
Concern about renal
function
RITZ-4i ACS 24–48 h
25–50 mg/h
192 72 h 3/95
(3.2%)
3/97
(3.1%)
12/95
(12.6%)
20/97
(20.6%)
More symptomatic
hypotension.
No adverse effect on ACS
RITZ-5j Pulmonary
edema
24 h
50–100 mg/h
84 1 m 2/42
(4.8%)
5/42
(11.9%)
16/42&
(38.1%)
16/42&
(38.1%)
Fall in arterial oxygen
saturation
Cotter et
al.k
Hemodynamics 24 h
0.2–25 mg/h
129 1 m 0/26
(0.0%)
5/103
(4.9%)
5/26
(19.2%)
17/103
(16.5%)
1 mg/h dose may sufﬁce
VERITASl Symptoms/
outcome
24–72 h
1 mg/h
1435 1 m 34/708
(4.8%)
28/727
(3.9%)
235/708#
(33.2%)
232/727#
(31.9%)
Symptoms not improved.
Fall in arterial oxygen
saturationT
C
2
2
folective) increased the risk of developing heart failure from 3.0% to 6.7%
(p=0.009) (Nelson et al., 2008) without any effect on survival, and
ﬂuid retention/edema development has also been recently reported to
occur in patients with prostate cancer treated with the ETA
receptor-speciﬁc antagonist zibotentan (Nelson et al., 2012), a drug de-
void of any activity on the ETB receptor (Rosano et al., 2007). Fluid re-
tention and edema during ERA therapy have also been reported in
studies of resistant hypertension (Weber et al., 2009), idiopathic pul-
monary arterial hypertension (Galie et al., 2008a,b), thrombo-embolic
pulmonary hypertension (Jais et al., 2008), coronary artery disease
(Raichlin et al., 2008; Reriani et al., 2010), and even in mountain sick-
ness (Modesti et al., 1998).
Fundamentally, ERAs appear tohave delivered their expected hemo-
dynamic effects but this has been offset by ﬂuid retention and indis-
criminate vasodilatation, an effect that may depend on the dose used
(Kelland and Webb, 2006). A healthy vasomotor system constricts
and dilates selectively to distribute blood ﬂow in an efﬁcient manner
to vital organs according to their metabolic demands (Cleland and
Oakley, 1991). Vasodilatation that is ‘unintelligent’ may direct blood
away from where it is most needed. Moreover, a fall in perfusion pres-
sure may have adverse consequences in heart failure, including activa-
tion of the renin–angiotensin and sympathetic nervous systems,
leading to sodium retention and further derangement in blood ﬂowdis-
tribution. A low blood pressure is a bad prognostic sign in heart failure
(Raphael et al., 2009). ERAs have worsened arterial oxygen saturation
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Failure to identify, manage, or understand these intricate aspects of ET
pathophysiology has undoubtedly contributed to the failure of clinical
research in this arena. In particular, the effects of ERAs on salt and
water homeostasis need to be understood. There is preliminary evi-
dence to suggest that an ETA receptor-mediated mechanism in the
collecting duct is responsible for ﬂuid retention following ETA receptor
blockade (Kohan et al., 2011a,b,c).
Is there still a future for ERAs in heart failure?
Surely there must be, but it would be foolish to conduct further re-
search without either better targeting of these agents or a better un-
derstanding of their effects on organ perfusion at the tissue level and
on renal salt and water handling. Pulmonary hypertension primarily
due to increased pulmonary vasomotor tone and subsequent right
heart failure appear to be an obvious target. However, in heart failure,
pulmonary hypertension is commonly due to left atrial hypertension
and secondary pulmonary vasoconstriction; typically, the pulmonary
artery systolic pressure at rest is only 40–50 mm Hg (Damy et al.,
2010). However, when the right ventricle starts to fail, pulmonary
vascular resistance may continue to climb without an increase in pul-
monary artery pressure but a downward spiral in blood ﬂow leading
to death (Damy et al., 2012). Finding a molecule (or a dose) that does
not cause sodium retention or an effective antidote to this effect
(Kohan et al., 2011a,b,c) might also transform the fortunes of ERAs.
Clearly, as with other neuro-endocrine antagonists, it may depend
not only on what you do but also on how you do it!
Endothelin receptor antagonists for therapy of pulmonary arterial
hypertension unrelated to heart failure
Early studies in experimental models of PAH as well as clinical
studies in PAH patients (Giaid et al., 1993) have demonstrated re-
markable up-regulation of ET-1 in the pulmonary arterial vascular
bed in diseased but not normal pulmonary arteries suggesting ET-1
might be a novel therapeutic target. This was also suggested by in-
creased circulating ET-1 levels in pulmonary hypertension (Cody et
al., 1992; Stewart et al., 1991; Yoshibayashi et al., 1991). Indeed,
while ET-1, a vasoconstrictor and a smooth muscle mitogen
(Komuro et al., 1988) has been implicated in the pathogenesis of a va-
riety of diseases (Barton and Yanagisawa, 2008), ET receptor blockade
has met with success as an efﬁcacious therapy for one particular con-
dition — pulmonary arterial hypertension (PAH).
Bosentan therapy in pulmonary arterial hypertension
The initial effort to evaluate bosentan, a non-selective ETA and ETB
receptor antagonist, in PAH, consisted of a small, double-blind,
placebo-controlled, multicenter study of 32 functional class III sub-
jects who were randomized to receive bosentan or placebo
(Channick et al., 2001). After 12 weeks, the mean six-minute walking
distance improved by 70 m in the bosentan arm, while no improve-
ment was seen with placebo. Bosentan improved hemodynamic pa-
rameters measured at cardiac catheterization as well, including an
increase in cardiac index and reduced mean pulmonary artery pres-
sure and pulmonary vascular resistance. Functional class also im-
proved in subjects treated with bosentan. A second double-blind,
placebo-controlled study evaluated bosentan in 213 patients with
PAH (either idiopathic or associated with connective tissue disease)
who were randomized to placebo or bosentan 125 or 250 mg bid
for a minimum of 16 weeks (62.5 mg bid for 4 weeks then target
dose) (Rubin et al., 2002). The primary endpoint was the change in
exercise capacity (assessed by six-minute walk), and secondary end-
points included changes in Borg dyspnea index, functional class, and
time from randomization to clinical worsening. After 16 weeks, thedifference between treatment groups in the mean change in
six-minute walk was 44 m in favor of bosentan. No dose response
for efﬁcacy could be ascertained. The risk of clinical worsening was
reduced by bosentan compared to placebo.
Abnormal hepatic function (as indicated by elevated levels of ala-
nine aminotransferase (ALT) and/or aspartate aminotransferase
(AST)), syncope, and ﬂushing occurred more frequently in the
bosentan group. Abnormal hepatic function was dose-dependent,
being more frequently reported as an adverse event in the high dos-
age bosentan group (250 mg bid) than in the low dosage group
(125 mg bid). McLaughlin et al. reported that open label, ﬁrst-line
therapy with bosentan, with the addition or transition to other ther-
apies as needed, resulted in Kaplan–Meier survival estimates of 96%
at 12 months and 89% at 24 months (McLaughlin et al., 2005). At
the end of 12 and 24 months, 85% and 70% of patients, respectively,
remained alive and on bosentan monotherapy. Sitbon et al. compared
open label survival in functional class III IPAH treated with bosentan
with historical data from similar patients treated with epoprostenol,
a parenterally-administered prostacyclin that was the ﬁrst and only
approved therapy for PAH prior to bosentan (Sitbon et al., 2005).
Baseline characteristics for the 139 patients treated with bosentan
and the 346 patients treated with epoprostenol suggested that the
epoprostenol cohort had more severe disease. Kaplan–Meier survival
estimates after 1 and 2 years were 97% and 91%, respectively, in the
bosentan-treated cohort and 91% and 84% in the epoprostenol cohort.
Bosentan therapy has also been evaluated by Galie et al. in a multi-
center, double-blind, randomized, and placebo-controlled study in
patients with functional class III Eisenmenger syndrome (Galie et
al., 2006). Fifty-four patients were randomized 2:1 to bosentan vs.
placebo for 16 weeks. Bosentan did not worsen oxygen saturation,
and compared with placebo, bosentan reduced pulmonary vascular
resistance index, decreased mean pulmonary arterial pressure, and
increased exercise capacity. Open label data with bosentan suggests
clinical improvements in HIV patients with PAH (Sitbon et al.,
2004), and preliminary data suggests beneﬁts in those with inopera-
ble chronic thromboembolic pulmonary hypertension (Jais et al.,
2008), as well as PAH patients with early stage disease (Galie et al.,
2008a,b).
Ambrisentan therapy in pulmonary arterial hypertension
Ambrisentan is a relatively selective antagonist of the ETA receptor.
A Phase-II dose-ranging study supported the efﬁcacy and safety of
ambrisentan in patients with PAH, and subsequently two pivotal
Phase-III clinical trials of ambrisentan in PAH conﬁrmed these ﬁndings
(Galie et al., 2005). Ambrisentan belongs to the group of carboxylic
ERAs which – unlike sulfonamide-based ERAs – are devoid of hepato-
toxicity. In fact, patients on ERAs with elevated liver function tests on
sulfonamide-based ERAs such as bosentan or sitaxentan have been suc-
cessfully switched to ambrisentan (Eriksson et al., 2011; McGoon et al.,
2009). Consequently, as of 2011 liver function tests are no longer re-
quired for patients receiving ambrisentan (MedPageToday.com).
Macitentan therapy in pulmonary arterial hypertension
Macitentan, a non-selective ETA/B receptor antagonist with beneﬁ-
cial effects in experimental pulmonary arterial hypertension (Iglarz
et al., 2008; Bolli et al., 2012) and diabetes-associated end-organ
injury (Sen et al., 2012), has been recently tested in a Phase III clinical
SERAPHIN trial in patients with pulmonary arterial hypertension. It is
the ﬁrst study using a morbidity/mortality composite endpoint
(Reuters.com). According to data announced on April 30, 2012
(Reuters.com), treatment with macitentan was associated with a 45%
risk reduction with the 10 mg dose and an approx. 30% risk reduction
with the 3 mg dose, suggesting a dose-dependent effect of the drug.
Fig. 2. Kaplan–Meier curves of the association between tumor of ET-1 protein expression
(assessed by immunohistochemistry) and disease-speciﬁc survival (DSS): A, in 92 patients
with bladder cancer with non-muscle invasive disease; B, in 102 patients with muscle inva-
sive stage disease.
Figure reproduced from Said et al. (2011) with permission of The Journal of Clinical
Investigation.
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conferences in Fall of 2012 (Reuters.com).
Previous experience with sitaxentan in pulmonary arterial hypertension
Sitaxentan, an ERAwith evengreater ETA selectivity thanambrisentan,
successfully evaluated for the therapy of pulmonary arterial hypertension
in two randomized, double-blind, placebo-controlled trials (Barst et al.,
2006, 2004) and improving exercise capacity and functional class after
12 weeks of treatment, had received regulatory approval for PAH in
Europe in 2007. However, sitaxentan was withdrawn from the market
after several fatal cases of hepatic failure in 2010 (Galie et al., 2011).
Factors determining the therapeutic efﬁcacy of eras in patients with
pulmonary arterial hypertension
Why has ERA therapy uniquely, but consistently, been effective in
pulmonary vascular disease? The answer is unclear. Possibilities include
1) the pathogenic role of ET may be most prominent in the highly
unique milieu of pulmonary vascular endothelial and smooth muscle
cells, which behave quite differently in a variety of circumstances and
in response to many stimuli from their systemic counterparts; 2) the
pulmonary vasculature is responsive to relatively low doses of ERAs,
while higher, and more toxic doses, may be necessary for systemic vas-
cular diseases. Also, the current clinical data suggests that selective and
non-selective ERAs are similarly efﬁcacious in improving clinical out-
come in PAH patients. More information in this regard is expected
from the results of ongoing Phase III clinical trials in PAH (Raja, 2010).
In addition, recently identiﬁed factors such as race- and sex differences
in response to ERA therapy (Gabler et al., 2012) aswell drug–drug inter-
actions observed during ERA therapy (Venitz et al., 2012; Pulido et al.,
2009; Srinivas, 2009; Walker et al., 2009; Harrison et al., 2010;
Spangler and Saxena, 2010) have to be taken into consideration when
treating PAH patients. Regardless of the explanation why ERAs are an
effective remedy in PAH, ERAs were the ﬁrst oral therapy for PAH, and
remain a critical component of the therapeutic algorithm for this
life-threatening disease. Further research is necessary to determine
long-term effects on disease modiﬁcation.
Endothelin receptor antagonism in patients with cancer
Endothelin is synthesized by cancer cells of different origin and stim-
ulates cancer cell growth (Bagnato and Rosano, 2008; Nelson et al.,
2003). More recently, the amount of ET-1 expression in tumor tissue
has been found to be a highly sensitive prognostic marker of survival
in patients with bladder cancer (Fig. 2) and circulating levels of big
ET-1 might predict early diagnosis in patients with invasive breast can-
cer (Kalles et al., 2012). Moreover, ET-1 – through its ETA receptor – has
been shown to crucially contribute to cancer cell metastasis (Said et al.,
2011) and lymphatic angiogenesis (Spinella et al., 2009). ETB-
receptor-mediated signaling has been identiﬁed as an inhibitory factor
of T cell homing to tumors, which could be enhanced by ETB antagonists
to enable tumor response to otherwise ineffective immunotherapy
(Buckanovich et al., 2008; Kandalaft et al., 2009). Endothelin – acting
on the unblocked ETB receptor during chronic ETA receptor blockade –
possibly might therefore interfere with targeted immunotherapies in
certain forms of cancer, actions that may be unrelated to the
anti-inﬂammatory and immunomodulatory effects of ERAs (Lattmann
et al., 2005; Nett et al., 2006; Sasser et al., 2007). In ovarian cancer,
endothelin has been identiﬁed to promote epithelial-to-mesenchymal
transition (Rosano et al., 2005); moreover, cell invasiveness andmetas-
tasis have been linked to ETA-receptor dependent, beta arrestin-mediat-
ed mechanisms that result in activation of beta catenin signaling
(Rosano et al., 2009). There is also evidence that the ET-1/ETA axis
plays a propagating role for pain transmission in bone metastasis in pa-
tients with therapy refractory prostate carcinoma (Cella et al., 2006;Jimeno and Carducci, 2006), indicating at least three therapeutic ave-
nues from which cancer patients might beneﬁt and experience im-
provements in quality of life or disease progression from ERA therapy.Evidence for a role of endothelin in metastatic colonization
In 2008, a review entitled “Metastasis: a therapeutic target for
cancer” (Steeg and Theodorescu, 2008) argued rather convincingly
that targeting the last step in the metastatic process, namely the out-
growth at a distant site, termed “metastatic colonization”, holds great
therapeutic promise. Such targeting can be of the tumor cell itself or
of the cancer cell–microenvironmental interactions that promote
tumor growth. The latter has been shown in elegantwork by the Pollard
and Karin labs to involve the host innate immune systemand speciﬁcal-
ly macrophages (Grivennikov et al., 2010; Qian and Pollard, 2010). In
2005, we reported that ET-1 secreted by tumors with low levels of the
RhoGDI2metastasis suppressorwas sensitive to inhibition ofmetastatic
colonizationwith the use of ETA receptor antagonists (Titus et al., 2005).
This was also seen in head and neck and other cancers (Growcott,
2009). This result led to further experiments that led to the striking
discovery that indeed, while ETA antagonists could reduce metastatic
colonization, they would not have any effect on established clinical
tumors at metastatic sites.
Further work over the next few years identiﬁed tumor secreted
ET-1 as a necessary mediator facilitating metastatic colonization via
chemoattraction of host macrophages to the metastatic site. More
importantly, recently published work (Said et al., 2011) explained
why ETA antagonists were progressively less effective as the tumor
grew in the lung indicating that the therapeutic window would best
be in the adjuvant setting. Given this data, it appears reasonable to
test the hypothesis in a clinical trial, that blockade of ETA receptors
via orally bioavailable small molecule antagonists will delay or reduce
the incidence of metastatic colonization in patients with high-risk
bladder cancer.
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In the last 10 years, two large pharmaceutical companies, Abbott
and Astra Zeneca, embarked on a systematic development and evalu-
ation program on their own ETA antagonists, atrasentan (Xinlay™)
and zibotentan (Nelson et al., 2012), respectively, in cancer. Since a
role of ET-1 in cancer was ﬁrst shown in prostate tumors and subse-
quent work implicated this molecule in prostate cancer bone metas-
tasis, the clinical work was focused on this cancer type (Lalich et al.,
2007; Russo et al., 2010). Following a promising Phase II program in
advanced metastatic disease, both companies undertook similar
Phase III trials which encompassed early metastatic disease, advanced
metastatic disease and combination therapy with ETA antagonists and
a taxane (the most effective chemotherapeutic in routine practice
today). Unfortunately, all 6 trials have proven to be negative, which
in retrospect, had we known of the critical yet time-sensitive role
of ET-1 in metastatic colonization, these trials, in patients with
established disease, would likely not have been done. Of course, the
“retrospectoscope” is 20:20 and we are fortunate that two companies
stepped up the plate and based on basic science data at the time
undertook the risky and costly challenge in doing these trials. Recent
clinical studies in oncology however suggest that ERAs may also be
useful as adjuvants to enhance anti-tumor effects of interferons in pa-
tients with renal cell carcinoma (Groenewegen et al., 2012), or to in-
hibit tumor growth in ovarian cancer patients by enhancing paclitaxel
efﬁcacy (Kim et al., 2011). Also, preclinical studies suggest the useful-
ness of ETB receptor agonists to enhance reduction in tumor volume
induced by radiation therapy (Gulati et al., 2011), an approach
which is now being tested in clinical trials (Tolcher et al., 2011).
Proposing to assess the efﬁcacy of ERAs in cancer metastasis
The research strategy is self-evident. We propose the “repurposing”
of atrasentan (Xinlay™ Abbott), zibotentan (Nelson et al., 2012) or
another ETA speciﬁc or ETA-selective inhibitor from pulmonary applica-
tions to a Phase II trial setting to test the hypothesis formulated above in
a clinical trial: will blockade of ETA via orally bioavailable small mole-
cule antagonists delay or reduce the incidence of metastatic coloniza-
tion and lymphatic angiogenesis in patients with high-risk bladder
cancer? In this proposed randomized Phase II trial, 108 or so high-risk
patients after cystectomywould be providedwith ETA antagonists oral-
ly and kept on them for 2 years which is the time frame where most
recurrences would occur in this patient population. Powered to detect
a 15% difference in recurrence compared to historical controls, this
trial would provide proof of principle of the concept that has been
discovered in experimental studies ofmetastasis. Given the novel scien-
tiﬁc foundation this trial is based upon, candidate biomarkers of
response in the patients' primary tumors could also be evaluated and
hence this trial wouldmake use of biospecimens collected in the course
of routine practice (i.e. the cystectomy specimen). The trial design,
patient population, selected agents (toxicity etc.) and biospecimen col-
lection (Lee et al., 2007; Said et al., 2011) make this a very feasible
research proposition. This trialwould not only be of great utility in blad-
der cancer but in other malignant diseases as well. For example, data
from other laboratories such as that of Anna Bagnato who studies ovar-
ian cancer have shown the importance of ET-1 in early dissemination in
this disease.
Why re-evaluate ERAs as therapeutics in oncology?
The trial design proposed above would embody several unique
aspects compared to other clinical investigations: 1) Rationally di-
rected therapeutic approach at the innate immune system to block
development ofmetastasis (i.e.metastatic colonization); 2) Repurposing
(Collins, 2011; Huang et al., 2011; Lee et al., 2007; Said et al., 2011)
known agents with extensive data in cancer patients and good safetyproﬁle thus saving millions of dollars in development; 3) Given the
rapid course of metastasis development in the selected population, the
trial could be completed in record time; and 4) The lack of standard alter-
natives or competing trials in the clinical situation described here indi-
cating an acute need for new therapeutics in the ﬁeld.
It would be an ironic twist of fate that our scientiﬁc advances have
now likely found one Achilles heel of metastatic colonization process
only to ﬁnd out we have neither the funding nor the small molecules
to test this hypothesis in patients. Is it possible that we have effective
drugs to prevent metastatic colonization that we can't now develop?
Are we victims of our past failures? Hopefully we can come together
as a scientiﬁc community to ﬁnd a solution to this problem and
should not be hesitant to design and conduct the appropriate studies
to test the therapeutic promise – as possible adjuvant therapeutics in
cancer patients – that these drugs still hold.
Current perspectives for ERA therapy in clinical medicine
Above, we have summarized the current state of ERA therapy
and problems encountered during clinical development of ERAs
during the past twenty years. As mentioned, most of these trials
were conducted when much of biology of ET and its receptors –
particularly in humans – was largely unknown. At the time when
studies were conducted, newly developed ERAs were given to
very sick patients – regardless of diagnoses were heart failure, can-
cer, or pulmonary arterial hypertension, or renal disease – at very
high doses, resulting in edema and ﬂuid retention, worsening their clin-
ical outcome. In particular, the only recent discovery that ETA receptor-
mediated ﬂuid retention/plasma volume expansion appears to be an
ERA class effect, that – if uncontrolled – will importantly determine
any ERA-associated health risk, aswas observed in prostate cancer trials
(Nelson et al., 2008) and in patients with advanced proteinuric kidney
disease (Mann et al., 2010) receiving very high ERA doses. Until we
have fully understood the mechanism and time course of this ERA-
inherent effect and until we have developed appropriate therapeutic
measures to circumvent this clinically relevant problem caution is ad-
vised. However, it appears that careful and early diuretic therapy can al-
leviate ERAmediated ﬂuid retention (Andress et al., 2012; Kohan et al.,
2011a,b,c).
The past decade, particularly through cell-speciﬁc or tissue-speciﬁc
manipulation of genes encoding for ET and its receptors has provided
important insights into ET biology in health and disease (Ahn et al.,
2004; Gariepy et al., 2000; Ge et al., 2005; Ivy et al., 2001; Kisanuki et
al., 2010; Shohet et al., 2004; Widyantoro et al., 2010; Zhao et al.,
2006). The fact thatmost of the clinical trials of ERAshave beennegative
or neutral, and the recent withdrawal of sitaxentan at the end of 2010
(Galie et al., 2011) (which had been approved for PAH three years
earlier by European agencies) has slowed down clinical research activ-
ity in this area. Opportunitiesmight have beenmissed since recent clin-
ical ERA trials were discontinued due to problems in patient
recruitment, while the short remaining patent life of certain ERAs
might have inﬂuenced discontinuation of clinical trials (Barton and
Kohan, 2011).
Currently, only two diseases (pulmonary arterial hypertension and
scleroderma-related digital ulcers (Dhillon, 2009)) have been approved
for ERA therapy. Orally active ERAs have also been successfully used as
snake venom antidotes for Atractaspis snake bites (Abd-Elsalam, 2011)
given the similarity of ET with viper venoms (Kloog et al., 1988). ERAs
could also become drug treatments for proteinuric renal disease
(Barton, 2008; Kohan et al., 2011a,b,c), therapy-resistant arterial hyper-
tension (Lazich and Bakris, 2011), cancer, chronic inﬂammatory and
auto-immune diseases such as systemic sclerosis and rheumatoid arthri-
tis (Kuryliszyn-Moskal et al., 2008;Muller-Ladner et al., 2009), and possi-
bly heart failure in carefully selected patients with mild-to-moderate
disease treated with the right doses of the right drug (Fig. 1). Optimiza-
tion of ERA dosing to minimize side effects appears to be possible, e.g.
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(Andress et al., 2012; Kohan et al., 2011a,b,c)., also alleviating hemody-
namic side effects including changes in blood pressure or GFR, effects
which are even greater in very sick patients suffering from CHF or
CKD that are already on a number of vasoactive drugs, particularly
ACEIs and ARBs which share some of the mechanisms of actions of
ERAs and endothelin production, respectively (Lariviere et al., 1998).
Changes of hemodynamics are more difﬁcult to cope for elderly pa-
tients, who also experience a gradual decline of GFR by 1% per year
starting at age 45. Novel pharmacological approaches to block either
binding or formation of ET by inhibiting ET converting enzymes
(Nelissen et al., 2012; Seed et al., 2012), or by combining ERAs with
drugs targeting other G protein-coupled receptors (Kowala et al.,
2004; Kurtz and Klein, 2009; Mohanan et al., 2011; Murugesan et al.,
2005; Neutel et al., 2008), may prove effective to block the ET pathway
in disease.
One of themajor drawbacks in the ﬁeld remains the lack of access to
many of the results obtained in clinical trials in the 1990s and early
2000s (Clozel, 2011; Kelland and Webb, 2007); this information
might provide valuable insights. Recently identiﬁed race- and sex differ-
ences in the effects of ERA therapy in PAH patients (Gabler et al., 2012),
ERA-drug interactions (Venitz et al., 2012) (Pulido et al., 2009; Srinivas,
2009; Walker et al., 2009; Harrison et al., 2010; Spangler and Saxena,
2010), and epigenetic regulation in PAH (Xu et al., 2011) require further
clinical research.
The previous disappointments in clinical development of ERAs
should not prevent us from exploring the potential of this class of
drugs using carefully designed and conducted clinical trials. There is
a limited amount of money to invest in new drugs, and every failure
of potential drug candidates implies a substantial loss of investment.
Provided that the now known side effects of plasma volume expan-
sion can be successfully controlled for, ERAs are promising drugs
since they are clearly antiproteinuric and hold potential for slowing
CKD progression (Barton, 2008), for improving the clinical course of
patients with PAH as suggested by the recently announced results
of the SERAPHIN trial (Reuters.com), and might have therapeutic po-
tential in selected patients with CHF or cancer. In addition, ERAs have
been found to reduce formation of new digital ulcers related to
scleroderma, but had no effect on healing existing ulcers (Korn et
al., 2004; Kuhn et al., 2010) (Fig. 1), effects that may be related to
the anti-inﬂammatory effects of ERAs in patients in with scleroderma
(Bellisai et al., 2011). Possibly, ERAs – via inhibiting the direct,
pro-inﬂammatory effects of endothelin-1 (Yang et al., 2004) – may
also be of therapeutic beneﬁt for other autoimmune diseases. There
still is the possibility that ERAs might be effective as therapeutics in
a variety of diseases, either alone or in combination with other
drugs, however for any clinical application of ERAs we still require
more data (and access to the substantial amount of unpublished
data (Kelland and Webb, 2007)), as well as outcome studies with de-
ﬁned and reasonable clinical endpoints. Using the lessons we have
learned, it should be possible to design and conduct successful trials
using these agents.
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